Boostrix® Pregnancy Registry

Completed

Conditions studied: Pertussis

In brief

The purpose of this Registry is to detect and describe any abnormal pregnancy outcomes, including teratogenicity, in females intentionally or unintentionally exposed to Boostrix during their pregnancies in the US. The Registry requires voluntary, prospective reporting of eligible pregnancies by patients and health care providers (HCPs). Data such as vaccination with Boostrix during pregnancy or within 28 days preceding conception, potential confounding factors (such as exposure to other medications) and information related to the outcome of the pregnancy will be collected prospectively

Key facts

Study ID
NCT02096276
Run by
GlaxoSmithKline
People needed
1517
Starts
2014-03-31
Expected to finish
2019-08-02
Last updated by the study team
2020-12-19

Who can join

Age: 12 and older, up to 64. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.